Toll Free: 1-888-928-9744
Published: Aug, 2014 | Pages:
1366 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Prostate Cancer - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Prostate Cancer - Pipeline Review, H2 2014', provides an overview of the Prostate Cancer's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Prostate Cancer and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Prostate Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Prostate Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Prostate Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Prostate Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Prostate Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Prostate Cancer pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 Introduction 11 Prostate Cancer Overview 12 Therapeutics Development 13 Prostate Cancer - Therapeutics under Development by Companies 15 Prostate Cancer - Therapeutics under Investigation by Universities/Institutes 36 Prostate Cancer - Pipeline Products Glance 41 Prostate Cancer - Products under Development by Companies 45 Prostate Cancer - Products under Investigation by Universities/Institutes 71 Prostate Cancer - Companies Involved in Therapeutics Development 77 Prostate Cancer - Therapeutics Assessment 313 Prostate Cancer - Recent Pipeline Updates 1039 Prostate Cancer - Dormant Projects 1283 Prostate Cancer - Discontinued Products 1312 Appendix 1314
List of Tables Number of Products under Development for Prostate Cancer, H2 2014 64 Number of Products under Development for Prostate Cancer - Comparative Analysis, H2 2014 65 Number of Products under Development by Companies, H2 2014 67 Number of Products under Development by Companies, H2 2014 (Contd..1) 68 Number of Products under Development by Companies, H2 2014 (Contd..2) 69 Number of Products under Development by Companies, H2 2014 (Contd..3) 70 Number of Products under Development by Companies, H2 2014 (Contd..4) 71 Number of Products under Development by Companies, H2 2014 (Contd..5) 72 Number of Products under Development by Companies, H2 2014 (Contd..6) 73 Number of Products under Development by Companies, H2 2014 (Contd..7) 74 Number of Products under Development by Companies, H2 2014 (Contd..8) 75 Number of Products under Development by Companies, H2 2014 (Contd..9) 76 Number of Products under Development by Companies, H2 2014 (Contd..10) 77 Number of Products under Development by Companies, H2 2014 (Contd..11) 78 Number of Products under Development by Companies, H2 2014 (Contd..12) 79 Number of Products under Development by Companies, H2 2014 (Contd..13) 80 Number of Products under Development by Companies, H2 2014 (Contd..14) 81 Number of Products under Development by Companies, H2 2014 (Contd..15) 82 Number of Products under Development by Companies, H2 2014 (Contd..16) 83 Number of Products under Development by Companies, H2 2014 (Contd..17) 84 Number of Products under Development by Companies, H2 2014 (Contd..18) 85 Number of Products under Development by Companies, H2 2014 (Contd..19) 86 Number of Products under Investigation by Universities/Institutes, H2 2014 88 Number of Products under Investigation by Universities/Institutes, H2 2014 (Contd..1) 89 Number of Products under Investigation by Universities/Institutes, H2 2014 (Contd..2) 90 Number of Products under Investigation by Universities/Institutes, H2 2014 (Contd..3) 91 Comparative Analysis by Late Stage Development, H2 2014 92 Comparative Analysis by Clinical Stage Development, H2 2014 93 Comparative Analysis by Early Stage Development, H2 2014 94 Comparative Analysis by Unknown Stage Development, H2 2014 95 Products under Development by Companies, H2 2014 96 Products under Development by Companies, H2 2014 (Contd..1) 97 Products under Development by Companies, H2 2014 (Contd..2) 98 Products under Development by Companies, H2 2014 (Contd..3) 99 Products under Development by Companies, H2 2014 (Contd..4) 100 Products under Development by Companies, H2 2014 (Contd..5) 101 Products under Development by Companies, H2 2014 (Contd..6) 102 Products under Development by Companies, H2 2014 (Contd..7) 103 Products under Development by Companies, H2 2014 (Contd..8) 104 Products under Development by Companies, H2 2014 (Contd..9) 105 Products under Development by Companies, H2 2014 (Contd..10) 106 Products under Development by Companies, H2 2014 (Contd..11) 107 Products under Development by Companies, H2 2014 (Contd..12) 108 Products under Development by Companies, H2 2014 (Contd..13) 109 Products under Development by Companies, H2 2014 (Contd..14) 110 Products under Development by Companies, H2 2014 (Contd..15) 111 Products under Development by Companies, H2 2014 (Contd..16) 112 Products under Development by Companies, H2 2014 (Contd..17) 113 Products under Development by Companies, H2 2014 (Contd..18) 114 Products under Development by Companies, H2 2014 (Contd..19) 115 Products under Development by Companies, H2 2014 (Contd..20) 116 Products under Development by Companies, H2 2014 (Contd..21) 117 Products under Development by Companies, H2 2014 (Contd..22) 118 Products under Development by Companies, H2 2014 (Contd..23) 119 Products under Development by Companies, H2 2014 (Contd..24) 120 Products under Development by Companies, H2 2014 (Contd..25) 121 Products under Investigation by Universities/Institutes, H2 2014 122 Products under Investigation by Universities/Institutes, H2 2014 (Contd..1) 123 Products under Investigation by Universities/Institutes, H2 2014 (Contd..2) 124 Products under Investigation by Universities/Institutes, H2 2014 (Contd..3) 125 Products under Investigation by Universities/Institutes, H2 2014 (Contd..4) 126 Products under Investigation by Universities/Institutes, H2 2014 (Contd..5) 127 Prostate Cancer - Pipeline by Baxter International Inc., H2 2014 128 Prostate Cancer - Pipeline by Johnson & Johnson, H2 2014 129 Prostate Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2014 130 Prostate Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 131 Prostate Cancer - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2014 132 Prostate Cancer - Pipeline by Amgen Inc., H2 2014 133 Prostate Cancer - Pipeline by Sanofi, H2 2014 134 Prostate Cancer - Pipeline by AstraZeneca PLC, H2 2014 135 Prostate Cancer - Pipeline by Eli Lilly and Company, H2 2014 136 Prostate Cancer - Pipeline by Viralytics Ltd., H2 2014 137 Prostate Cancer - Pipeline by GlaxoSmithKline plc, H2 2014 138 Prostate Cancer - Pipeline by Bioniche Life Sciences, Inc., H2 2014 139 Prostate Cancer - Pipeline by Genentech, Inc., H2 2014 140 Prostate Cancer - Pipeline by Bavarian Nordic A/S, H2 2014 141 Prostate Cancer - Pipeline by Isis Pharmaceuticals, Inc., H2 2014 142 Prostate Cancer - Pipeline by Daiichi Sankyo Company, Limited, H2 2014 143 Prostate Cancer - Pipeline by Merck & Co., Inc., H2 2014 144 Prostate Cancer - Pipeline by Emergent BioSolutions Inc., H2 2014 145 Prostate Cancer - Pipeline by Oxford BioMedica plc, H2 2014 146 Prostate Cancer - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 147 Prostate Cancer - Pipeline by Amorfix Life Sciences Ltd., H2 2014 148 Prostate Cancer - Pipeline by Ipsen S.A., H2 2014 149 Prostate Cancer - Pipeline by MediGene AG, H2 2014 150 Prostate Cancer - Pipeline by Bio-Path Holdings, Inc., H2 2014 151 Prostate Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H2 2014 152 Prostate Cancer - Pipeline by Novartis AG, H2 2014 153 Prostate Cancer - Pipeline by Samyang Holdings Corporation, H2 2014 154 Prostate Cancer - Pipeline by Aphios Corporation, H2 2014 155 Prostate Cancer - Pipeline by Astellas Pharma Inc., H2 2014 156 Prostate Cancer - Pipeline by GTx, Inc., H2 2014 157 Prostate Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2014 158 Prostate Cancer - Pipeline by Orion Corp, H2 2014 159 Prostate Cancer - Pipeline by Pfizer Inc., H2 2014 160 Prostate Cancer - Pipeline by Astex Pharmaceuticals, Inc., H2 2014 161 Prostate Cancer - Pipeline by Teva Pharmaceutical Industries Limited, H2 2014 162 Prostate Cancer - Pipeline by Genmab A/S, H2 2014 163 Prostate Cancer - Pipeline by Progenics Pharmaceuticals, Inc., H2 2014 164 Prostate Cancer - Pipeline by Exelixis, Inc., H2 2014 165 Prostate Cancer - Pipeline by Aduro BioTech, Inc., H2 2014 166 Prostate Cancer - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2014 167 Prostate Cancer - Pipeline by Ferring International Center S.A., H2 2014 168 Prostate Cancer - Pipeline by Celgene Corporation, H2 2014 169 Prostate Cancer - Pipeline by Onyx Pharmaceuticals, Inc., H2 2014 170 Prostate Cancer - Pipeline by Bayer AG, H2 2014 171 Prostate Cancer - Pipeline by AntiCancer, Inc., H2 2014 172 Prostate Cancer - Pipeline by Merck KGaA, H2 2014 173 Prostate Cancer - Pipeline by Advaxis, Inc., H2 2014 174 Prostate Cancer - Pipeline by 4SC AG, H2 2014 175 Prostate Cancer - Pipeline by Alchemia Limited, H2 2014 176 Prostate Cancer - Pipeline by Harbor Therapeutics, Inc., H2 2014 177 Prostate Cancer - Pipeline by Celldex Therapeutics, Inc., H2 2014 178 Prostate Cancer - Pipeline by Anavex Life Sciences Corp., H2 2014 179 Prostate Cancer - Pipeline by ValiRx Plc, H2 2014 180 Prostate Cancer - Pipeline by Active Biotech AB, H2 2014 181 Prostate Cancer - Pipeline by AEterna Zentaris Inc., H2 2014 182 Prostate Cancer - Pipeline by Immunomedics, Inc., H2 2014 183 Prostate Cancer - Pipeline by Antisense Therapeutics Limited, H2 2014 184 Prostate Cancer - Pipeline by Arrowhead Research Corporation, H2 2014 185 Prostate Cancer - Pipeline by Lorus Therapeutics Inc., H2 2014 186 Prostate Cancer - Pipeline by MEI Pharma, Inc., H2 2014 187 Prostate Cancer - Pipeline by Bionomics Limited, H2 2014 188 Prostate Cancer - Pipeline by Northwest Biotherapeutics, Inc., H2 2014 189 Prostate Cancer - Pipeline by Novogen Limited, H2 2014 190 Prostate Cancer - Pipeline by Nymox Pharmaceutical Corporation, H2 2014 191 Prostate Cancer - Pipeline by Oncolytics Biotech Inc., H2 2014 192 Prostate Cancer - Pipeline by Oncothyreon Inc., H2 2014 193 Prostate Cancer - Pipeline by Compugen Ltd., H2 2014 194 Prostate Cancer - Pipeline by OXiGENE, Inc., H2 2014 195 Prostate Cancer - Pipeline by Patrys Limited, H2 2014 196 Prostate Cancer - Pipeline by Medivation, Inc., H2 2014 197 Prostate Cancer - Pipeline by ArQule, Inc., H2 2014 198 Prostate Cancer - Pipeline by Regeneron Pharmaceuticals, Inc., H2 2014 199 Prostate Cancer - Pipeline by Oncogenex Pharmaceuticals, Inc., H2 2014 200 Prostate Cancer - Pipeline by ProMetic Life Sciences Inc., H2 2014 201 Prostate Cancer - Pipeline by Galectin Therapeutics, Inc., H2 2014 202 Prostate Cancer - Pipeline by AnGes MG, Inc., H2 2014 203 Prostate Cancer - Pipeline by Quest PharmaTech Inc., H2 2014 204 Prostate Cancer - Pipeline by Synta Pharmaceuticals Corp., H2 2014 205 Prostate Cancer - Pipeline by Natco Pharma Limited, H2 2014 206 Prostate Cancer - Pipeline by Sareum Holdings plc, H2 2014 207 Prostate Cancer - Pipeline by Oasmia Pharmaceutical AB, H2 2014 208 Prostate Cancer - Pipeline by DiaMedica Inc., H2 2014 209 Prostate Cancer - Pipeline by Dongkook Pharmaceutical Co., Ltd., H2 2014 210 Prostate Cancer - Pipeline by Galena Biopharma, Inc., H2 2014 211 Prostate Cancer - Pipeline by Hybrigenics S.A., H2 2014 212 Prostate Cancer - Pipeline by Rexahn Pharmaceuticals, Inc., H2 2014 213 Prostate Cancer - Pipeline by Merrion Pharmaceuticals Plc, H2 2014 214 Prostate Cancer - Pipeline by Nanobiotix, H2 2014 215 Prostate Cancer - Pipeline by Solasia Pharma K.K., H2 2014 216 Prostate Cancer - Pipeline by Fujifilm Corporation, H2 2014 217 Prostate Cancer - Pipeline by Antigen Express, Inc., H2 2014 218 Prostate Cancer - Pipeline by Affitech A/S, H2 2014 219 Prostate Cancer - Pipeline by Isarna Therapeutics GmbH, H2 2014 220 Prostate Cancer - Pipeline by Colby Pharmaceutical Company, H2 2014 221 Prostate Cancer - Pipeline by Mayne Pharma Group Limited, H2 2014 222 Prostate Cancer - Pipeline by Chipscreen Biosciences Ltd, H2 2014 223 Prostate Cancer - Pipeline by CIMAB S.A., H2 2014 224 Prostate Cancer - Pipeline by Supratek Pharma Inc., H2 2014 225 Prostate Cancer - Pipeline by Camurus AB, H2 2014 226 Prostate Cancer - Pipeline by Fusion Antibodies Ltd, H2 2014 227 Prostate Cancer - Pipeline by Actinium Pharmaceuticals, Inc., H2 2014 228 Prostate Cancer - Pipeline by CellCentric Ltd., H2 2014 229 Prostate Cancer - Pipeline by Med Discovery SA, H2 2014 230 Prostate Cancer - Pipeline by Pro-Cure Therapeutics Limited, H2 2014 231 Prostate Cancer - Pipeline by immatics biotechnologies GmbH, H2 2014 232 Prostate Cancer - Pipeline by LIDDS AB, H2 2014 233 Prostate Cancer - Pipeline by Vaxon Biotech, H2 2014 234 Prostate Cancer - Pipeline by Advantagene, Inc., H2 2014 235 Prostate Cancer - Pipeline by CureVac GmbH, H2 2014 236 Prostate Cancer - Pipeline by Medeia Therapeutics Ltd., H2 2014 237 Prostate Cancer - Pipeline by Aileron Therapeutics, Inc., H2 2014 238 Prostate Cancer - Pipeline by Alethia Biotherapeutics Inc., H2 2014 239 Prostate Cancer - Pipeline by GenSpera, Inc., H2 2014 240 Prostate Cancer - Pipeline by Ascenta Therapeutics, Inc., H2 2014 241 Prostate Cancer - Pipeline by Tokai Pharmaceuticals, Inc., H2 2014 242 Prostate Cancer - Pipeline by Coronado Biosciences, Inc., H2 2014 243 Prostate Cancer - Pipeline by MacroGenics, Inc., H2 2014 244 Prostate Cancer - Pipeline by Provenance Biopharmaceuticals Corp., H2 2014 245 Prostate Cancer - Pipeline by Antyra, Inc., H2 2014 246 Prostate Cancer - Pipeline by Ambrx, Inc., H2 2014 247 Prostate Cancer - Pipeline by Arno Therapeutics, Inc., H2 2014 248 Prostate Cancer - Pipeline by Orphagen Pharmaceuticals, Inc., H2 2014 249 Prostate Cancer - Pipeline by Pantarhei Bioscience BV, H2 2014 250 Prostate Cancer - Pipeline by Azaya Therapeutics Incorporated, H2 2014 251 Prostate Cancer - Pipeline by Semafore Pharmaceuticals, Inc., H2 2014 252 Prostate Cancer - Pipeline by GP Pharm, S.A., H2 2014 253 Prostate Cancer - Pipeline by IC-MedTech, Inc., H2 2014 254 Prostate Cancer - Pipeline by Innate Therapeutics Limited, H2 2014 255 Prostate Cancer - Pipeline by ProNAi Therapeutics, Inc., H2 2014 256 Prostate Cancer - Pipeline by Angion Biomedica Corp., H2 2014 257 Prostate Cancer - Pipeline by Axelar AB, H2 2014 258 Prostate Cancer - Pipeline by Endocyte, Inc., H2 2014 259 Prostate Cancer - Pipeline by Omnitura Therapeutics Inc., H2 2014 260 Prostate Cancer - Pipeline by AndroScience Corporation, H2 2014 261 Prostate Cancer - Pipeline by Pharminox Limited, H2 2014 262 Prostate Cancer - Pipeline by Immutep S.A., H2 2014 263 Prostate Cancer - Pipeline by Esperance Pharmaceuticals, Inc., H2 2014 264 Prostate Cancer - Pipeline by Mirna Therapeutics, Inc., H2 2014 265 Prostate Cancer - Pipeline by Omeros Corporation, H2 2014 266 Prostate Cancer - Pipeline by TransTech Pharma, Inc., H2 2014 267 Prostate Cancer - Pipeline by Immunovaccine, Inc., H2 2014 268
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.